Revvity Valuation
Is 0KHE undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0KHE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 0KHE ($111.22) is trading below our estimate of fair value ($125.31)
Significantly Below Fair Value: 0KHE is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0KHE?
Key metric: As 0KHE is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 0KHE's PE Ratio? | |
|---|---|
| PE Ratio | 52.4x |
| Earnings | US$258.26m |
| Market Cap | US$13.52b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 5.7x |
| Enterprise Value/EBITDA | 19.8x |
| PEG Ratio | 2.6x |
Price to Earnings Ratio vs Peers
How does 0KHE's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 30x | ||
ERGO Ergomed | 46.7x | 14.2% | UK£701.1m |
HVO hVIVO | 8.6x | -15.2% | UK£149.7m |
HIK Hikma Pharmaceuticals | 19x | 12.8% | UK£4.3b |
AVTR Avantor | 45.7x | 36.4% | US$13.9b |
0KHE Revvity | 52.4x | 20.1% | US$13.5b |
Price-To-Earnings vs Peers: 0KHE is expensive based on its Price-To-Earnings Ratio (52.4x) compared to the peer average (24.1x).
Price to Earnings Ratio vs Industry
How does 0KHE's PE Ratio compare vs other companies in the European Life Sciences Industry?
| 1 Company | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 1 Company | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: 0KHE is expensive based on its Price-To-Earnings Ratio (52.4x) compared to the European Life Sciences industry average (37.4x).
Price to Earnings Ratio vs Fair Ratio
What is 0KHE's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 52.4x |
| Fair PE Ratio | 30.7x |
Price-To-Earnings vs Fair Ratio: 0KHE is expensive based on its Price-To-Earnings Ratio (52.4x) compared to the estimated Fair Price-To-Earnings Ratio (30.7x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$112.28 | US$138.95 +23.8% | 8.2% | US$162.17 | US$120.00 | n/a | 18 |
| Nov ’25 | US$122.45 | US$137.90 +12.6% | 8.4% | US$162.17 | US$120.00 | n/a | 18 |
| Oct ’25 | US$125.96 | US$133.87 +6.3% | 7.8% | US$162.00 | US$120.00 | n/a | 18 |
| Sep ’25 | US$121.12 | US$133.87 +10.5% | 7.8% | US$162.00 | US$120.00 | n/a | 18 |
| Aug ’25 | US$124.13 | US$134.10 +8.0% | 7.9% | US$162.00 | US$120.00 | n/a | 17 |
| Jul ’25 | US$105.36 | US$124.04 +17.7% | 9.9% | US$162.00 | US$105.00 | n/a | 16 |
| Jun ’25 | US$107.90 | US$123.67 +14.6% | 10.3% | US$162.00 | US$105.00 | n/a | 16 |
| May ’25 | US$102.01 | US$123.61 +21.2% | 10.3% | US$162.00 | US$105.00 | n/a | 16 |
| Apr ’25 | US$105.47 | US$123.11 +16.7% | 10.6% | US$162.00 | US$100.00 | n/a | 16 |
| Mar ’25 | US$108.09 | US$123.11 +13.9% | 10.6% | US$162.00 | US$100.00 | n/a | 16 |
| Feb ’25 | US$109.69 | US$117.66 +7.3% | 15.1% | US$162.00 | US$85.00 | n/a | 16 |
| Jan ’25 | US$109.90 | US$104.79 -4.6% | 16.5% | US$162.00 | US$85.00 | n/a | 17 |
| Dec ’24 | US$91.07 | US$106.71 +17.2% | 17.0% | US$162.00 | US$85.00 | n/a | 14 |
| Nov ’24 | US$82.05 | US$106.71 +30.1% | 17.0% | US$162.00 | US$85.00 | US$122.45 | 14 |
| Oct ’24 | US$111.67 | US$143.24 +28.3% | 9.9% | US$170.00 | US$120.00 | US$125.96 | 16 |
| Sep ’24 | US$119.47 | US$144.31 +20.8% | 9.1% | US$170.00 | US$125.00 | US$121.12 | 16 |
| Aug ’24 | US$123.65 | US$143.74 +16.3% | 9.9% | US$170.00 | US$120.00 | US$124.13 | 16 |
| Jul ’24 | US$118.19 | US$145.53 +23.1% | 11.1% | US$170.00 | US$120.00 | US$105.36 | 15 |
| Jun ’24 | US$116.00 | US$147.19 +26.9% | 11.4% | US$170.00 | US$120.00 | US$107.90 | 15 |
| May ’24 | US$130.42 | US$155.78 +19.4% | 9.1% | US$182.00 | US$134.00 | US$102.01 | 14 |
| Apr ’24 | US$130.97 | US$158.92 +21.3% | 8.0% | US$182.00 | US$140.00 | US$105.47 | 12 |
| Mar ’24 | US$124.04 | US$158.92 +28.1% | 8.0% | US$182.00 | US$140.00 | US$108.09 | 12 |
| Feb ’24 | US$140.72 | US$160.00 +13.7% | 8.3% | US$185.00 | US$140.00 | US$109.69 | 12 |
| Jan ’24 | n/a | US$157.92 0% | 9.3% | US$178.00 | US$127.00 | US$109.90 | 12 |
| Dec ’23 | US$132.68 | US$156.18 +17.7% | 12.0% | US$192.00 | US$127.00 | US$91.07 | 11 |
| Nov ’23 | US$137.15 | US$166.91 +21.7% | 14.1% | US$202.00 | US$120.00 | US$82.05 | 11 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Laboratorios Farmaceuticos Rovi
€3.2b
Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.
0ILL
€62.90
7D
1.5%
1Y
14.6%
hVIVO
UK£149.7m
Operates as a pharmaceutical service and contract research company in the United Kingdom.
HVO
UK£0.22
7D
-16.2%
1Y
22.2%
Regeneron Pharmaceuticals
US$80.1b
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
0R2M
US$746.89
7D
-1.9%
1Y
-6.5%